Published in Heart on December 01, 1998
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
British Hypertension Society guidelines for hypertension management 1999: summary. BMJ (1999) 8.80
Risk factor thresholds: their existence under scrutiny. BMJ (2002) 5.55
Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ (2003) 4.74
The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract (2005) 3.65
Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ (2003) 2.97
By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart (2005) 2.32
Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes. BMJ (2003) 2.22
Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med (2003) 2.22
Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart (2003) 2.20
Guidelines on preventing cardiovascular disease in clinical practice. BMJ (2000) 2.15
Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ (2003) 2.06
Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart (2002) 1.98
Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart (2002) 1.98
How effective are rapid access chest pain clinics? Prognosis of incident angina and non-cardiac chest pain in 8762 consecutive patients. Heart (2006) 1.98
Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods. BMJ (2000) 1.92
Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart (2007) 1.91
Clustering of risk factors and social class in childhood and adulthood in British women's heart and health study: cross sectional analysis. BMJ (2004) 1.66
Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res (2008) 1.65
Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia (2009) 1.65
Diabetes care needs evidence based interventions to reduce risk of vascular disease. BMJ (2000) 1.57
Paying for statins. BMJ (2004) 1.57
Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol (2002) 1.57
Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart (2006) 1.56
Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2010) 1.46
Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart (2002) 1.44
Effective diabetes care: a need for realistic targets. BMJ (2002) 1.43
Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study. Int J Clin Pract (2013) 1.41
Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ (2000) 1.40
Can computerised decision support systems deliver improved quality in primary care?. Interview by Abi Berger. BMJ (1999) 1.31
The rise of cholesterol testing: how much is unnecessary. Br J Gen Pract (2011) 1.27
Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vasc Health Risk Manag (2008) 1.26
Assessment of total cardiovascular risk using WHO/ISH risk prediction charts in three low and middle income countries in Asia. BMC Public Health (2013) 1.23
Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Fam Pract (2011) 1.16
Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. Am J Cardiol (2007) 1.11
A laboratory based intervention to improve appropriateness of lipid tests and audit cholesterol lowering in primary care. BMJ (2001) 1.11
Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. Qual Saf Health Care (2006) 1.11
The development of a simulation model of primary prevention strategies for coronary heart disease. Health Care Manag Sci (2002) 1.10
Barriers to apply cardiovascular prediction rules in primary care: a postal survey. BMC Fam Pract (2007) 1.08
Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open (2015) 1.07
Reference right atrial dimensions and volume estimation by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2013) 1.04
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol (2003) 1.02
Treating dyslipidaemia in primary care. The gap between policy and reality is large in the UK. BMJ (2000) 1.00
Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol (2003) 0.98
Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ (2004) 0.98
Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK). Scand J Prim Health Care (2007) 0.96
National service framework for coronary heart disease. Ambiguities need to be clarified. BMJ (2000) 0.95
Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol (2002) 0.95
'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol (2008) 0.94
Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. Curr Control Trials Cardiovasc Med (2001) 0.92
Analysis of predicted coronary heart disease risk in England based on Framingham study risk appraisal models published in 1991 and 2000. BMJ (2002) 0.92
Cholesterol lowering margarine may not be useful in healthy fat modified diet. BMJ (1999) 0.90
Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors. BMC Med Inform Decis Mak (2004) 0.90
The applicability of the Framingham coronary heart disease prediction function to black and minority ethnic groups in the UK. Heart (2003) 0.88
Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol (2009) 0.86
Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol (2008) 0.86
Predictors of patients' preferences for treatments to prevent heart disease. Heart (2006) 0.84
Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart (2005) 0.84
Sharing risk management: an implementation model for cardiovascular absolute risk assessment and management in Australian general practice. Int J Clin Pract (2008) 0.82
Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk. Heart (2005) 0.82
Lipid lowering to delay the progression of coronary artery disease. Heart (2003) 0.82
The current status of primary prevention in coronary heart disease. Curr Control Trials Cardiovasc Med (2001) 0.79
Dyslipidemia guidelines. CMAJ (2004) 0.78
Cardiovascular and coronary risk estimation in hypertension management. Heart (2002) 0.78
Management of dyslipidaemia. Heart (2004) 0.77
HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. Clin Biochem Rev (2004) 0.77
Estimation of 10-Year Risk of Coronary Heart Disease in Nepalese Patients with Type 2 Diabetes: Framingham Versus United Kingdom Prospective Diabetes Study. N Am J Med Sci (2015) 0.77
Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy. Vasc Health Risk Manag (2008) 0.77
American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart (2006) 0.76
Cohort study investigating the relationship between cholesterol, cardiovascular risk score and the prescribing of statins in UK primary care: study protocol. BMJ Open (2016) 0.75
Financial incentives improve recognition but not treatment of cardiovascular risk factors in severe mental illness. PLoS One (2017) 0.75
Randomized trial evaluating the framing of cardiovascular risk and its impact on blood pressure control [ISRCTN87597585]. BMC Health Serv Res (2001) 0.75
Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used? Heart (2002) 0.75
Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. Br J Gen Pract (2005) 0.75
Risk factor thresholds. Threshold is 37 000 pounds sterling per QALY. BMJ (2002) 0.75
CORONARY RISK ANALYSIS - A STITCH IN TIME. Med J Armed Forces India (2011) 0.75
Drugs used in secondary prevention after myocardial infarction: case presentation. Br J Clin Pharmacol (2000) 0.75
Concomitant detection of systemic atherosclerotic disease while screening for abdominal aortic aneurysm. World J Surg (2006) 0.75
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA (1989) 14.34
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ (1994) 11.85
An updated coronary risk profile. A statement for health professionals. Circulation (1991) 11.71
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med (1994) 11.65
Should there be a moratorium on the use of cholesterol lowering drugs? BMJ (1992) 9.85
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet (1991) 9.57
Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (1989) 9.27
Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet (1994) 9.13
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet (1985) 8.35
Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ (1993) 8.24
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care (1997) 7.85
The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med (1993) 7.69
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol (1990) 7.24
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med (1993) 6.45
Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ (1997) 6.32
Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ (1993) 6.23
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 5.82
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Assessing possible hazards of reducing serum cholesterol. BMJ (1994) 5.61
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 5.46
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med (1993) 5.14
Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J (1998) 5.09
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) (1987) 5.01
Recommendations on blood pressure measurement. Br Med J (Clin Res Ed) (1986) 4.97
Benefits and potential harm of lowering high blood pressure. Lancet (1987) 4.88
Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet (1980) 4.86
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med (1977) 4.53
Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol (1989) 4.53
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol (1995) 4.50
Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA (1988) 4.46
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ (1990) 4.23
An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med (1995) 4.08
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Exercise in leisure time: coronary attack and death rates. Br Heart J (1990) 4.01
Management of raised blood pressure in New Zealand: a discussion document. BMJ (1993) 3.96
Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A (1973) 3.94
By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction. BMJ (1991) 3.47
Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med (1990) 3.29
Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N Z Med J (1993) 3.18
Dietary reduction of serum cholesterol concentration: time to think again. BMJ (1991) 3.10
Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull (1994) 3.09
Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J (1988) 3.05
Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev (1987) 2.88
Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) (1996) 2.88
The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med (1990) 2.85
Working party report on cardiac rehabilitation. Br Heart J (1992) 2.81
Hypotensive therapy in stroke survivors. Lancet (1970) 2.78
Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA (1990) 2.78
Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med (1997) 2.78
By how much does dietary salt reduction lower blood pressure? I--Analysis of observational data among populations. BMJ (1991) 2.72
An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation (1990) 2.63
Ethnic differences in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure. Lancet (1991) 2.55
Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. JAMA (1987) 2.55
Alcohol and blood pressure: the INTERSALT study. BMJ (1994) 2.41
Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. The British Family Heart Study. Arch Fam Med (1997) 2.41
Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med (1997) 2.40
The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med (1996) 2.32
Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens (1998) 2.28
Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med (1986) 2.26
Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension (1989) 2.18
Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med (1994) 2.09
Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med (1994) 2.06
Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J (Clin Res Ed) (1983) 2.05
Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet (1998) 2.02
Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med (1990) 1.95
Perspectives on systolic hypertension. The Framingham study. Circulation (1980) 1.92
Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med (1991) 1.85
Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia (1992) 1.79
WHO clofibrate/cholesterol trial: clarifications. Lancet (1992) 1.79
Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron (1982) 1.76
Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ (1995) 1.75
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care (1992) 1.75
Blood-pressure-lowering effect of a vegetarian diet: controlled trial in normotensive subjects. Lancet (1983) 1.74
Treating mild hypertension. Report of the British Hypertension Society working party. BMJ (1989) 1.73
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) Lancet (1995) 1.63
How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol (1991) 1.56
Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med (1971) 1.55
Concordance for coronary risk factors among spouses. Circulation (1975) 1.44
Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ (1991) 1.44
Vegetarian diet in mild hypertension: a randomised controlled trial. Br Med J (Clin Res Ed) (1986) 1.40